Crown Holdings just reported its Q1 2026 results — and the market's verdict has been a measured step back.
The stock ended April 29 at $99.02, down 2.8% on the week and briefly breaking below the $100 level that served as informal support through much of March. The immediate post-earnings drop of around 2.5% on April 28 is modest by historical standards, but the direction is clear: a result that wasn't bad enough to panic, but not good enough to re-rate.
The analyst response tells that story directly. Citi bucked the trend, lifting its Buy-rated target from $127 to $129 — still the most constructive name on the Street. But JP Morgan cut its target from $115 to $107 while staying Neutral, and UBS trimmed from $120 to $112 with the same Neutral rating. Truist and Wells Fargo both made smaller trims in the two weeks before earnings. The net direction is clearly lower targets across the neutral-to-cautious part of the Street, even as the bulls hold their ground. The consensus mean sits at $125, implying roughly 26% upside from current levels — a gap that reflects genuine disagreement about the path back to that valuation, not a consensus view that it's easy.
The fundamental divide is real. Bulls point to European beverage can volumes running around 10% above year-ago levels, eight consecutive quarters of earnings beats, and improving can-making equipment efficiencies expected to build through 2026. Bears flag declining Asia-Pacific volumes — down roughly 3% year-on-year — rising raw material cost risks, and growing international exposure at a moment when the macro backdrop is unstable. At a P/E of 12x and EV/EBITDA near 8x, doesn't price in much optimism. Both multiples have compressed modestly over the past month. The EV/EBITDA multiple has drifted about 0.14 turns lower over 30 days — not a dramatic re-rating, but consistent with a market that is being patient rather than enthusiastic.
Short interest adds relatively little drama to this setup. At 4.5% of the free float, it has climbed roughly 23% over the past month in share terms — moving from around 4.5 million shares to 5.1 million. That's a meaningful build in the context of this name's history, though the absolute level remains well below crowded territory. Borrowing costs are inexpensive at 0.37%, down 30% from last week's brief spike, and borrow availability is loose — only about 6% of available shares have been lent out, against a 52-week high of 17%. There is no squeeze pressure here, and no signal that the short side is becoming structurally committed. Shorts appear to be tactical rather than convicted.
Options positioning offers a clearer read on near-term sentiment. The put/call ratio has dropped sharply to 0.35, running well below its 20-day average of 0.47 — nearly 1.6 standard deviations on the call-heavy side. That makes it the most call-skewed reading in weeks. It could reflect hedges coming off after the earnings event, or active call buying from investors playing a bounce from the $99 level. Either way, options traders are not positioned defensively right now.
CEO Timothy Donahue sold 15,000 shares across two transactions in April — roughly $1.6 million at prices between $105 and $107 — both before the earnings release. Those sales now sit above the current market price. The 90-day net insider position, when awards are included, is a modest net positive in share count, so the sales appear routine rather than directional. But the timing, above current levels, gives pause to anyone leaning hard on management conviction as a bullish catalyst.
The factor scores reinforce the value-with-caveats framing. CCK ranks in the 93rd percentile for analyst recommendation divergence — meaning the spread between bulls and bears is unusually wide — and scores in the 80th percentile on EV/EBIT, signalling cheapness on an earnings basis. The dividend score is in the 99th percentile, though the dividend history data is stale and the actual yield is a modest 1.2%. The short score of 41 is unremarkable and consistent with a name where shorts are building slowly but not rushing. The RSI is sitting around 41, modestly oversold.
Closest peers had a rough week too: BALL fell 3%, SLGN dropped 4.8%, and AMCR slid 6.2%, suggesting the weakness is sector-wide rather than company-specific. SON was the standout loser in the group, off 12% on the week. Against that backdrop, CCK's 2.8% decline looks relatively contained.
The next focal point is whether the combination of a compressed multiple, wide analyst target gaps, and a sector under macro pressure resolves into a floor around $99 — or whether the Street's softening targets continue to walk the stock lower.
See the live data behind this article on ORTEX.
Open CCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
